Literature DB >> 17425471

Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder.

Richard H Weisler1.   

Abstract

A number of long-acting medications for the treatment of attention deficit hyperactivity disorder (ADHD) have recently been developed and approved for use in the US. These compounds are intended to optimize and maintain ADHD symptom control throughout the day, while eliminating problems associated with short-acting medications, such as the need for in-school, midday or multiple daily doses. Recent reports confirm that the safety and tolerability of long-acting medications are similar to those of short-acting medications, although long-acting medications appear to have a lower risk of abuse and diversion and may be associated with significant improvements in medication adherence. Distinctions can be made among the long-acting medications with regard to the onset, magnitude and duration of their clinical effects. Recognition of these differences is important for individualizing treatment for patients with ADHD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17425471     DOI: 10.1517/14656566.8.6.745

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  9 in total

Review 1.  A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.

Authors:  Martin A Katzman; Tia Sternat
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

2.  Treating attention-deficit/hyperactivity disorder in adults: focus on once-daily medications.

Authors:  Richard H Weisler; Ann C Childress
Journal:  Prim Care Companion CNS Disord       Date:  2011

3.  Childhood health: trends and consequences over the life course.

Authors:  Liam Delaney; James P Smith
Journal:  Future Child       Date:  2012

Review 4.  Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults.

Authors:  Sharon B Wigal
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

5.  Short-acting versus Long-acting Medications for the Treatment of ADHD.

Authors:  Elisa Cascade; Amir H Kalali; Richard H Weisler
Journal:  Psychiatry (Edgmont)       Date:  2008-08

6.  Osmotic release oral system-methylphenidate improves neural activity during low reward processing in children and adolescents with attention-deficit/hyperactivity disorder.

Authors:  Kei Mizuno; Tetsuya Yoneda; Masanori Komi; Toshinori Hirai; Yasuyoshi Watanabe; Akemi Tomoda
Journal:  Neuroimage Clin       Date:  2013-03-16       Impact factor: 4.881

7.  Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day.

Authors:  Sharon B Wigal; Scott H Kollins; Ann C Childress; Ben Adeyi
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2010-12-14       Impact factor: 3.033

Review 8.  Adult ADHD and comorbid disorders: clinical implications of a dimensional approach.

Authors:  Martin A Katzman; Timothy S Bilkey; Pratap R Chokka; Angelo Fallu; Larry J Klassen
Journal:  BMC Psychiatry       Date:  2017-08-22       Impact factor: 3.630

9.  Adult Patient Preferences for Long-Acting ADHD Treatments: A Discrete Choice Experiment.

Authors:  M Janelle Cambron-Mellott; Jaromir Mikl; Joana E Matos; Jennifer G Erensen; Kathleen Beusterien; Marc J Cataldo; Bernadette Hallissey; Gregory W Mattingly
Journal:  Patient Prefer Adherence       Date:  2021-05-21       Impact factor: 2.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.